Novo Nordisk's pricing approaches inside the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who has accused the company of rate gouging, mentioning the stark distinction among U.S. rates and people in Europe and copyright.California biotech behemoth Amgen ditched options for an experimental weight loss pill in May but remains